Sáez-Llorens X, Castrejón de Wong M C, Castaño E, de Suman O, Báez de Ulloa C, Redondo W, Espino M
Hospital del Niño de Panamá.
Rev Med Panama. 2001;26:13-8.
Although the neurological manifestations of HIV infection occur at any age, children with perinatal AIDS are affected earlier and with greater impact. There are no published data about a potential association between HIV encephalopathy and viral load in THE CSF OF the pediatric population.
Twenty-three children, aged 7 months to 10 years, were studied as part of a multicenter international study that evaluated double versus triple antiretroviral therapy. Samples of CSF and plasma were collected for HIV RNA measurements on day 0 and on follow-up weeks 8, 16, and 48. Neurological assessments, psychological evaluations, and CT scans were done on admission and at study end. Viral isolates were processed for genotypic resistance.
No correlation between viral load in CSF and plasma was detected at study onset. Eighty percent of children had >2 log HIV RNA in CSF at day 0 but only 30% at week 16. Eight subjects responded favorably to therapy and their CSF had undetectable viral load during follow-up determinations. On day 0, 72% of children had identical patterns of genotypic resistance in CSF and plasma samples. At week 48, however, only 11% of these subjects had identical patterns. On day 0, 83% of children had abnormal neurological findings but these alterations declined to 35% at week 48 (p = 0.004). Most children with neurological abnormalities had detectable CSF viral loads (65% vs 17%, p = 0.04).
The data generated in this study suggest that CSF and plasma behave as two different body compartments in terms of HIV dynamics and resistance mutants. Presence of neurological abnormalities correlate with detection of HIV in CSF and these alterations improve as therapy decreases CSF viral load. These results underscore the importance of using ARV drugs with good CNS penetration for optimal management of HIV-infected young children.
尽管HIV感染的神经学表现可发生于任何年龄,但围产期艾滋病患儿受影响更早且影响更大。关于小儿群体脑脊液中HIV脑病与病毒载量之间潜在关联,尚无公开数据。
作为一项评估双药与三药抗逆转录病毒疗法的多中心国际研究的一部分,对23名年龄在7个月至10岁的儿童进行了研究。在第0天以及随访的第8、16和48周采集脑脊液和血浆样本以检测HIV RNA。入院时和研究结束时进行神经学评估、心理评估和CT扫描。对病毒分离株进行基因型耐药性检测。
研究开始时未检测到脑脊液和血浆中病毒载量之间的相关性。80%的儿童在第0天脑脊液中的HIV RNA>2 log,但在第16周时仅为30%。8名受试者对治疗反应良好,其脑脊液在随访检测期间病毒载量不可测。在第0天,72%的儿童脑脊液和血浆样本中的基因型耐药模式相同。然而,在第48周时,这些受试者中只有11%具有相同模式。在第0天,83%的儿童有异常神经学表现,但这些改变在第48周时降至35%(p = 0.004)。大多数有神经学异常的儿童脑脊液病毒载量可测(65%对17%,p = 0.04)。
本研究得出的数据表明,就HIV动态变化和耐药突变体而言,脑脊液和血浆表现为两个不同的身体腔室。神经学异常的存在与脑脊液中HIV的检测相关,并且随着治疗使脑脊液病毒载量降低,这些改变会改善。这些结果强调了使用具有良好中枢神经系统渗透性的抗逆转录病毒药物对HIV感染幼儿进行最佳管理的重要性。